Endocyte Company Profile (NASDAQ:ECYT)

About Endocyte (NASDAQ:ECYT)

Endocyte logoEndocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin (EC1456), the Company's second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company's non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:ECYT
  • CUSIP: 29269A10
  • Web: www.endocyte.com
  • Market Cap: $110.85 million
  • Outstanding Shares: 42,470,000
Average Prices:
  • 50 Day Moving Avg: $2.40
  • 200 Day Moving Avg: $2.48
  • 52 Week Range: $1.98 - $4.15
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.18
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $70,000.00
  • Price / Sales: 1,583.52
  • Book Value: $2.98 per share
  • Price / Book: 0.88
  • EBIDTA: ($41,570,000.00)
  • Net Margins: -57,108.57%
  • Return on Equity: -25.17%
  • Return on Assets: -24.29%
  • Current Ratio: 32.65%
  • Quick Ratio: 32.65%
  • Average Volume: 368,270 shs.
  • Beta: 1.84
  • Short Ratio: 5.89

Frequently Asked Questions for Endocyte (NASDAQ:ECYT)

What is Endocyte's stock symbol?

Endocyte trades on the NASDAQ under the ticker symbol "ECYT."

How were Endocyte's earnings last quarter?

Endocyte, Inc. (NASDAQ:ECYT) released its earnings results on Wednesday, May, 10th. The company reported ($0.27) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.28) by $0.01. The firm earned $0.01 million during the quarter. Endocyte had a negative return on equity of 25.17% and a negative net margin of 57,108.57%. The business's revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.24) earnings per share. View Endocyte's Earnings History.

Where is Endocyte's stock going? Where will Endocyte's stock price be in 2017?

3 analysts have issued 1-year price objectives for Endocyte's shares. Their predictions range from $7.00 to $7.00. On average, they anticipate Endocyte's stock price to reach $7.00 in the next twelve months. View Analyst Ratings for Endocyte.

What are analysts saying about Endocyte stock?

Here are some recent quotes from research analysts about Endocyte stock:

  • 1. According to Zacks Investment Research, "Endocyte reported a narrower than expected a loss in the first quarter of 2017. Currently, the company is focused on the development of two candidates, EC1456 and EC1169, both of which are currently in early-stage studies. The company is working on the development of companion imaging agents that help to identify patients who will benefit from its product, upon approval. Further, Endocyte’s successful development of targeted small-molecule drug conjugates (SMDCs) that are able to penetrate deep into dense solid tumors and have a shorter half-life could help the company gain an edge over existing therapies However, with no approved product in its portfolio at the moment, Endocyte has to depend heavily on its partners for top-line growth. Shares of the company have underperformed in the Medical-Drugs industry." (5/19/2017)
  • 2. Cowen and Company analysts commented, "Today a late breaking abstract was presented at the AACR conference with pre-." (4/5/2017)

Are investors shorting Endocyte?

Endocyte saw a increase in short interest in April. As of April 13th, there was short interest totalling 1,647,183 shares, an increase of 0.1% from the March 31st total of 1,646,029 shares. Based on an average trading volume of 242,836 shares, the short-interest ratio is currently 6.8 days.

Who are some of Endocyte's key competitors?

Who owns Endocyte stock?

Endocyte's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (8.26%), Vanguard Group Inc. (3.84%), Pinnacle Associates Ltd. (1.90%), JPMorgan Chase & Co. (1.44%), Geode Capital Management LLC (0.64%) and RMB Capital Management LLC (0.62%). Company insiders that own Endocyte stock include Christopher P Leamon, Fred A Middleton and Philip S Low. View Institutional Ownership Trends for Endocyte.

Who sold Endocyte stock? Who is selling Endocyte stock?

Endocyte's stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Morgan Stanley, Oxford Asset Management, Pinnacle Associates Ltd., California Public Employees Retirement System and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Endocyte.

Who bought Endocyte stock? Who is buying Endocyte stock?

Endocyte's stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Renaissance Technologies LLC, Algert Global LLC, Parametric Portfolio Associates LLC, Dimensional Fund Advisors LP, Ameriprise Financial Inc., FMR LLC and RMB Capital Management LLC. Company insiders that have bought Endocyte stock in the last two years include Fred A Middleton and Philip S Low. View Insider Buying and Selling for Endocyte.

How do I buy Endocyte stock?

Shares of Endocyte can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Endocyte stock cost?

One share of Endocyte stock can currently be purchased for approximately $2.61.

Analyst Ratings

Consensus Ratings for Endocyte (NASDAQ:ECYT) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.00 (168.20% upside)

Analysts' Ratings History for Endocyte (NASDAQ:ECYT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/11/2017WedbushReiterated RatingOutperformHighView Rating Details
4/5/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
11/11/2016Credit Suisse Group AGReiterated RatingBuy$7.00N/AView Rating Details
11/4/2015Royal Bank of CanadaLower Price TargetOutperform$13.00 -> $10.00N/AView Rating Details
9/8/2015Cantor FitzgeraldReiterated RatingBuy$21.00N/AView Rating Details
(Data available from 5/23/2015 forward)


Earnings History for Endocyte (NASDAQ:ECYT)
Earnings by Quarter for Endocyte (NASDAQ:ECYT)
Earnings History by Quarter for Endocyte (NASDAQ:ECYT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.28)($0.27)$0.01 millionViewN/AView Earnings Details
3/10/2017Q4 2016($0.25)($0.26)$0.01 millionViewN/AView Earnings Details
11/9/2016Q316($0.27)($0.21)$0.03 millionViewListenView Earnings Details
8/4/2016Q2($0.26)($0.25)$0.01 millionViewN/AView Earnings Details
5/4/2016Q116($0.25)($0.24)$0.01 millionViewListenView Earnings Details
3/2/2016Q4($0.27)($0.23)$0.01 millionViewListenView Earnings Details
11/3/2015Q315($0.27)($0.24)$0.03 millionViewN/AView Earnings Details
8/4/2015Q215($0.30)($0.25)$0.01 millionViewN/AView Earnings Details
5/7/2015Q115($0.24)($0.26)$0.01 millionViewN/AView Earnings Details
3/2/2015Q414($0.24)($0.19)$2.55 million$12.00 millionViewN/AView Earnings Details
11/5/2014Q314($0.21)($0.14)$5.10 million$3.90 millionViewN/AView Earnings Details
7/29/2014Q214$0.11$0.52$26.62 million$49.17 millionViewN/AView Earnings Details
5/2/2014Q114($0.15)($0.09)$15.07 million$17.30 millionViewN/AView Earnings Details
2/24/2014Q413($0.14)($0.08)$15.90 million$17.30 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.06)($0.11)$14.24 million$14.50 millionViewN/AView Earnings Details
4/15/2013Q413($0.10)$8.50 million$13.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Endocyte (NASDAQ:ECYT)
2017 EPS Consensus Estimate: ($1.32)
2018 EPS Consensus Estimate: ($0.88)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.32)($0.32)($0.32)
Q2 20171($0.33)($0.33)($0.33)
Q3 20171($0.33)($0.33)($0.33)
Q4 20171($0.34)($0.34)($0.34)
Q1 20181($0.30)($0.30)($0.30)
Q2 20181($0.19)($0.19)($0.19)
Q3 20181($0.19)($0.19)($0.19)
Q4 20181($0.20)($0.20)($0.20)
(Data provided by Zacks Investment Research)


Dividend History for Endocyte (NASDAQ:ECYT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Endocyte (NASDAQ:ECYT)
Insider Ownership Percentage: 16.62%
Institutional Ownership Percentage: 37.04%
Insider Trades by Quarter for Endocyte (NASDAQ:ECYT)
Institutional Ownership by Quarter for Endocyte (NASDAQ:ECYT)
Insider Trades by Quarter for Endocyte (NASDAQ:ECYT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/30/2016Christopher P. LeamonVPSell23,244$2.55$59,272.20View SEC Filing  
5/10/2016Philip S LowInsiderBuy11,375$3.52$40,040.00View SEC Filing  
1/19/2016Fred A. MiddletonDirectorBuy10,000$2.79$27,900.00View SEC Filing  
1/15/2016Fred A. MiddletonDirectorBuy20,000$2.80$56,000.00View SEC Filing  
4/9/2014Allen RitterVPSell1,000$21.16$21,160.00View SEC Filing  
3/21/2014Allen RitterVPSell8,000$33.11$264,880.00View SEC Filing  
2/14/2014Philip LowInsiderSell6,000$15.00$90,000.00View SEC Filing  
12/2/2013P Ron EllisCEOSell3,000$12.00$36,000.00View SEC Filing  
9/16/2013Allen RitterVPSell2,000$17.06$34,120.00View SEC Filing  
9/12/2013David MeekInsiderSell10,000$15.50$155,000.00View SEC Filing  
9/3/2013P Ron EllisCEOSell3,000$14.54$43,620.00View SEC Filing  
8/30/2013Allen RitterVPSell6,000$14.36$86,160.00View SEC Filing  
8/6/2013Chandra LovejoyVPSell7,000$17.29$121,030.00View SEC Filing  
8/1/2013P Ron EllisCEOSell3,000$18.12$54,360.00View SEC Filing  
7/15/2013P Ron EllisCEOSell3,000$17.01$51,030.00View SEC Filing  
5/28/2013Ann HanhamDirectorSell9,900$14.10$139,590.00View SEC Filing  
5/22/2013Ann HanhamDirectorSell40,000$14.38$575,200.00View SEC Filing  
5/17/2013Ann HanhamDirectorSell37,200$14.41$536,052.00View SEC Filing  
5/17/2013Binh NguyenVPSell17,300$14.42$249,466.00View SEC Filing  
5/15/2013Ann HanhamDirectorSell40,200$14.69$590,538.00View SEC Filing  
5/14/2013Christopher P LeamonVPSell5,000$14.70$73,500.00View SEC Filing  
2/25/2013Chandra D LovejoyVPSell2,102$9.70$20,389.40View SEC Filing  
12/26/2012Chandra D LovejoyVPSell2,209$9.05$19,991.45View SEC Filing  
11/26/2012Chandra D LovejoyVPSell2,209$8.72$19,262.48View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Endocyte (NASDAQ:ECYT)
Latest Headlines for Endocyte (NASDAQ:ECYT)
americanbankingnews.com logoEndocyte, Inc. (ECYT) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - May 19 at 11:29 PM
finance.yahoo.com logoEndocyte (ECYT) Focused on Two Lead Pipeline Candidates
finance.yahoo.com - May 19 at 8:08 AM
americanbankingnews.com logoBrokers Issue Forecasts for Endocyte, Inc.'s Q1 2018 Earnings (ECYT)
www.americanbankingnews.com - May 15 at 9:10 AM
americanbankingnews.com logoWedbush Weighs in on Endocyte, Inc.'s FY2021 Earnings (ECYT)
www.americanbankingnews.com - May 12 at 6:56 PM
americanbankingnews.com logoWedbush Reiterates Outperform Rating for Endocyte, Inc. (ECYT)
www.americanbankingnews.com - May 11 at 10:10 AM
finance.yahoo.com logoInvestor Network: Endocyte, Inc. to Host Earnings Call
finance.yahoo.com - May 10 at 10:05 PM
finance.yahoo.com logoEndocyte Reports First Quarter Financial Results and Provides Clinical and Pipeline Update
finance.yahoo.com - May 10 at 10:05 PM
finance.yahoo.com logoEdited Transcript of ECYT earnings conference call or presentation 10-May-17 12:30pm GMT
finance.yahoo.com - May 10 at 10:05 PM
finance.yahoo.com logoEndocyte (ECYT) Reports Narrower than Expected Q1 Loss
finance.yahoo.com - May 10 at 5:03 PM
americanbankingnews.com logoEndocyte, Inc. (ECYT) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - May 10 at 4:34 PM
marketbeat.com logoEndocyte reports 1Q loss
marketbeat.com - May 10 at 8:33 AM
americanbankingnews.com logoEndocyte, Inc. (ECYT) Sees Large Growth in Short Interest
www.americanbankingnews.com - May 10 at 7:18 AM
americanbankingnews.com logo-$0.28 Earnings Per Share Expected for Endocyte, Inc. (ECYT) This Quarter
www.americanbankingnews.com - May 8 at 10:27 PM
finance.yahoo.com logoEndocyte Announces First Quarter 2017 Earnings Conference Call
finance.yahoo.com - May 3 at 4:46 PM
americanbankingnews.com logoSomewhat Negative Media Coverage Likely to Affect Endocyte (ECYT) Share Price
www.americanbankingnews.com - May 3 at 12:06 PM
finance.yahoo.com logoWhat to Expect from Endocyte (ECYT) Stock for Q1 Earnings?
finance.yahoo.com - May 1 at 4:44 PM
americanbankingnews.com logoPositive Media Coverage Very Likely to Impact Endocyte (ECYT) Share Price
www.americanbankingnews.com - April 21 at 7:34 PM
americanbankingnews.com logoEndocyte, Inc. (ECYT) Expected to Announce Earnings of -$0.28 Per Share
www.americanbankingnews.com - April 18 at 12:25 PM
americanbankingnews.com logoEndocyte (ECYT) Receives Daily News Impact Score of 0.44
www.americanbankingnews.com - April 15 at 10:07 AM
finance.yahoo.com logoEndocyte (ECYT) Up 3.5% Since Earnings Report: Can It Continue?
finance.yahoo.com - April 10 at 11:49 AM
streetinsider.com logoEndocyte (ECYT) Presents Data Identifying Multiple Methods for Managing Severe Side Effects Resulting from CAR T ... - StreetInsider.com
www.streetinsider.com - April 7 at 9:50 PM
finance.yahoo.com logoEndocyte Presents Data at AACR Identifying Multiple Methods for Managing Severe Side Effects Resulting from CAR T-Cell Treatment
finance.yahoo.com - April 7 at 9:33 AM
americanbankingnews.com logoEndocyte, Inc. (ECYT) Receives "Buy" Rating from Cowen and Company
www.americanbankingnews.com - April 5 at 4:09 PM
streetinsider.com logoEndocyte (ECYT) Announces Eight Poster Presentations at at AACR
www.streetinsider.com - March 28 at 12:05 PM
us.rd.yahoo.com logo6:24 pm Endocyte announces presentations at American Association for Cancer Research April 1-5 Meeting to include late-breaker highlighting Endocyte's next generation CAR T-cell therapeutic platform
us.rd.yahoo.com - March 28 at 12:05 PM
finance.yahoo.com logoEndocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2017
finance.yahoo.com - March 27 at 4:41 PM
finance.yahoo.com logoENDOCYTE INC Financials
finance.yahoo.com - March 17 at 5:11 PM
finance.yahoo.com logoEndocyte (ECYT) Shares March Higher, Can It Continue?
finance.yahoo.com - March 14 at 12:58 PM
biz.yahoo.com logoENDOCYTE INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 13 at 4:57 PM
americanbankingnews.com logoEndocyte, Inc. Forecasted to Post FY2021 Earnings of $0.72 Per Share (ECYT)
www.americanbankingnews.com - March 13 at 2:48 PM
finance.yahoo.com logoEdited Transcript of ECYT earnings conference call or presentation 10-Mar-17 1:30pm GMT
finance.yahoo.com - March 13 at 12:00 PM
americanbankingnews.com logoEndocyte, Inc. (ECYT) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - March 10 at 2:45 PM
us.rd.yahoo.com logoEndocyte and Seattle Children’s Research Institute to Collaborate on Endocyte’s Small Molecule Drug Conjugate Bi-Specific Adaptor Molecules for CAR T-cell Therapies
us.rd.yahoo.com - March 10 at 11:37 AM
us.rd.yahoo.com logoEndocyte Reports Fourth Quarter and Year End 2016 Financial Results and Provides Clinical and Pipeline Update
us.rd.yahoo.com - March 10 at 11:37 AM
biz.yahoo.com logoENDOCYTE INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial S
us.rd.yahoo.com - March 10 at 11:37 AM
finance.yahoo.com logoEndocyte (ECYT) Reports a Wider Q4 Loss
finance.yahoo.com - March 10 at 11:37 AM
seekingalpha.com logoEndocyte (ECYT) Presents At Cowen and Company 37th Annual Health Care Conference
seekingalpha.com - March 8 at 10:49 PM
finance.yahoo.com logoEndocyte Announces Fourth Quarter and Full Year 2016 Earnings Conference Call
finance.yahoo.com - March 2 at 5:09 PM
finance.yahoo.com logoEndocyte to Present at the Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - March 1 at 4:37 PM
zacks.com logoEndocyte (ECYT) to Post Q4 Earnings: What's in the Cards?
www.zacks.com - February 23 at 4:52 PM
streetinsider.com logoEndocyte (ECYT) Appoints Michael Andriole as CFO
www.streetinsider.com - February 22 at 5:08 PM
streetinsider.com logoEndocyte (ECYT) Appoints Michael Andriole as CFO - StreetInsider.com
www.streetinsider.com - February 22 at 7:16 AM
finance.yahoo.com logoEndocyte Appoints Michael T. Andriole as Chief Financial Officer
finance.yahoo.com - February 22 at 7:16 AM
finance.yahoo.com logo8:17 am Endocyte appoints Michael T. Andriole as CFO
finance.yahoo.com - February 22 at 7:16 AM
biz.yahoo.com logoENDOCYTE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
biz.yahoo.com - February 22 at 7:16 AM
finance.yahoo.com logoValeant to Sell Dendreon Unit to Sanpower for $820 Million
finance.yahoo.com - January 10 at 5:50 PM
finance.yahoo.com logoIs Valeant (VRX) Fated for Terrible 2017 As Well?
finance.yahoo.com - January 3 at 6:49 PM



Endocyte (ECYT) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff